Endovascular Treatment of Femoral-Popliteal Disease

ABSTRACT

Available and improved options for the treatment of femoral-popliteal disease have increased over the last decade. Even though most patients suffering from claudication due to femoral-popliteal disease are treated with aggressive medical and noninvasive methods, patients with limb-threatening disease and severely lifestyle-limiting symptoms are treated with invasive treatments, which include endovascular treatment options. Unfortunately, the unique forces involved in this vascular segment have challenged the long-term patency and clinical effectiveness of these treatments. The purpose of this brief review is to discuss treatment strategies and options for patients with femoral-popliteal disease. Included in this discussion will be the review of data from recent published studies and late-breaking trials as it pertains to certain treatment strategies.

KEYWORDS

Superficial femoral artery - angioplasty - stent - claudication - critical limb ischemia

REFERENCES

• 1 Newman A B, Shemanski L, Manolio T A The Cardiovascular Health Study Group et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study.  Arterioscler Thromb Vasc Biol. 1999;  19 538-545
• 2 Hirsch A T, Haskal Z J, Hertzer N R American Association for Vascular Surgery et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.  J Am Coll Cardiol. 2006;  47 1239-1312
• 3 Sharafuddin M J, Stolpen A H, Dixon B S, Andresen K J, Sun S, Lawton W J. Value of MR angiography before percutaneous transluminal renal artery angioplasty and stent placement.  J Vasc Interv Radiol. 2002;  13(9 Pt 1) 901-908
• 4 Norgren L, Hiatt W R, Dormandy J A, Nehler M R, Harris K A, Fowkes F G. TASC II Working Group . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).  J Vasc Surg. 2007;  45(Suppl S) S5-S67
• 5 Bradbury A, Gamgee S. Long term (5 year) results of BASIL Trial Show “Open Surgery First” to be Superior to “Endovascular Treatment First” for Critical Limb Ischemia. Presented at: Veith Symposium November 2008 New York;
• 6 Adam D J, Beard J D, Cleveland T BASIL trial participants et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.  Lancet. 2005;  366 1925-1934
• 7 Yilmaz S, Sindel T, Lüleci E. Ultrasound-guided retrograde popliteal artery catheterization: experience in 174 consecutive patients.  J Endovasc Ther. 2005;  12 714-722
• 8 Spinosa D J, Harthun N L, Bissonette E A et al.. Subintimal arterial flossing with antegrade-retrograde intervention (SAFARI) for subintimal recanalization to treat chronic critical limb ischemia.  J Vasc Interv Radiol. 2005;  16 37-44
• 9 Bolia A, Brennan J, Bell P R. Recanalisation of femoro-popliteal occlusions: improving success rate by subintimal recanalisation.  Clin Radiol. 1989;  40 325
• 10 Nadal L L, Cynamon J, Lipsitz E C, Bolia A. Subintimal angioplasty for chronic arterial occlusions.  Tech Vasc Interv Radiol. 2004;  7 16-22
• 11 Met R, Van Lienden K P, Koelemay M J, Bipat S, Legemate D A, Reekers J A. Subintimal angioplasty for peripheral arterial occlusive disease: a systematic review.  Cardiovasc Intervent Radiol. 2008;  31 687-697
• 12 Clark T W, Groffsky J L, Soulen M C. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry.  J Vasc Interv Radiol. 2001;  12 923-933
• 13 Krankenberg H, Schlüter M, Steinkamp H J et al.. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST).  Circulation. 2007;  116 285-292
• 14 Duda S H, Pusich B, Richter G et al.. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results.  Circulation. 2002;  106 1505-1509
• 15 Duda S H, Bosiers M, Lammer J et al.. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial.  J Vasc Interv Radiol. 2005;  16 331-338
• 16 Scheinert D, Scheinert S, Sax J et al.. Prevalence and clinical impact of stent fractures after femoropopliteal stenting.  J Am Coll Cardiol. 2005;  45 312-315
• 17 Schillinger M, Sabeti S, Loewe C et al.. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery.  N Engl J Med. 2006;  354 1879-1888
• 18 Katzen B. Veith Symposium; November 23, 2008. New York. Update and new findings from the resilient trial comparing the life stent with POBA: improvement with stenting is durable beyond one year Available at: http://www.medicalnewstoday.com/articles/130504.php
• 19 Laird J, Jaff M R, Biamino G et al.. Cryoplasty for the treatment of femoropopliteal arterial disease: results of a prospective, multicenter registry.  J Vasc Interv Radiol. 2005;  16 1067-1073
• 20 Saxon R R, Coffman J M, Gooding J M, Ponec D J. Long-term patency and clinical outcome of the Viabahn stent-graft for femoropopliteal artery obstructions.  J Vasc Interv Radiol. 2007;  18 1341-1349 quiz 1350
• 21 Saxon R R, Dake M D, Volgelzang R L, Katzen B T, Becker G J. Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease.  J Vasc Interv Radiol. 2008;  19 823-832
• 22 Tepe G, Zeller T, Albrecht T et al.. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.  N Engl J Med. 2008;  358 689-699
• 23 Bosiers M. Melopee study 12 months results. International Symposium on Endovascular therapy (ISET) Conference January 22, 2008 Hollywood, FL;
• 24 Idelchik G M, Dougherty K G, Hernandez E, Mortazavi A, Strickman N E, Krajcer Z. Endovascular exclusion of popliteal artery aneurysms with stent-grafts: a prospective single-center experience.  J Endovasc Ther. 2009;  16 215-223
• 25 Fowkes F G, Housley E, Cawood E H, Macintyre C C, Ruckley C V, Prescott R J. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population.  Int J Epidemiol. 1991;  20 384-392
• 26 Selvin E, Marinopoulos S, Berkenblit G et al.. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.  Ann Intern Med. 2004;  141 421-431
• 27 O'Hare A M, Vittinghoff E, Hsia J, Shlipak M G. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS).  J Am Soc Nephrol. 2004;  15 1046-1051